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Abstract
Background: Scientific evidence for the frequency of monitoring of type 2 diabetes patients is lacking. If three-
monthly control in general practice could be reduced to six-monthly control in some patients, this would on the one 
hand reduce the use of medical services including involvement of practice nurses, and thus reduce costs, and on the 
other hand alleviate the burden of people with type 2 diabetes. The goal of this study is to make primary diabetes care 
as efficient as possible for patients and health care providers. Therefore, we want to determine whether six-monthly 
monitoring of well-controlled type 2 diabetes patients in primary care leads to equivalent cardiometabolic control 
compared to the generally recommended three-monthly monitoring.
Methods and design: The study is a randomised controlled patient-preference equivalence trial. Participants are 
asked if they prefer three-monthly (usual care) or six-monthly diabetes monitoring. If they do not have a preference, 
they are randomised to a three-monthly or six-monthly monitoring group. Patients are eligible for the study if they are 
between 40 and 80 years old, diagnosed with type 2 diabetes more than one year ago, treated by a general 
practitioner, not on insulin treatment, and with HbA1c ≤7.5%, systolic blood pressure ≤145 mmHg and total 
cholesterol ≤5.2 mmol/l. The intervention group (six-monthly monitoring) will receive the same treatment with the 
same treatment targets as the control group (three-monthly monitoring). The intervention period will last one and a 
half year. After the intervention, the three-monthly and six-monthly monitoring groups are compared on equivalence 
of cardiometabolic control. Secondary outcome measures are HbA1c, blood pressure, cholesterol level, Body Mass 
Index, smoking behaviour, physical activity, loss of work due to illness, health status, diabetes-specific distress, 
satisfaction with treatment and adherence to medications. We will use intention-to-treat analysis with repeated 
measures. For outcomes that have only baseline and final measurements, we will use ANCOVA. Depending on the 
results, a cost-minimisation analysis or an incremental cost-effectiveness analysis will be done.
Discussion: This study will provide valuable information on the most efficient control frequency of well-controlled 
type 2 diabetes patients in primary care.
Trial registration: Current Controlled Trials ISRCTN93201802
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At the end of 2007 more than 660.000 people were diag-
nosed with type 2 diabetes in the Netherlands [1]. The
number of type 2 diabetes patients is still increasing [1],
and also their use of health care facilities. Furthermore,
the overall workload of general practitioners is increasing
[2]. The current guideline on type 2 diabetes in primary
care in the Netherlands advises to monitor type 2 diabe-
tes patients four times a year [3], but this advice is not
evidence-based. Three quarterly controls are done by the
practice nurse and the general practitioner is advised to
perform the annual check-up. Comparing 15 diabetes
guidelines in 13 countries, the advised frequency of mon-
itoring HbA1c ranged from one to four times a year and
monitoring blood pressure ranged from one to six times a
year [4]. It is obvious that the workload for healthcare
professionals will differ significantly, depending on the
guideline that is followed.
A retrospective, observational study in Spain demon-
strated that the improvement in glycaemic control over
time in patients with type 2 diabetes in general practice
was not related to the number of visits to the general
practitioner, but to changes in treatment [5]. More evi-
dence on the desired frequency of type 2 diabetes con-
trols in general practice is lacking.
A randomised equivalence trial in Canada compared
blood pressure control, adherence to treatment and
patient satisfaction in patients with treated hypertension
followed up by their family physicians every three or six
months. Patients with follow-up every three months
achieved the same levels of blood pressure control, adher-
ence to treatment and patient satisfaction compared to
patients with follow-up every six months [6].
If, in accordance with the hypertension example, the
contact time with the diabetes team in well-controlled
type 2 diabetes patients could also be reduced up to 50%
without deteriorating their quality of care, this could
reduce the patient burden as well as induce savings on
direct medical costs and relieve the workload of practice
nurses.
Therefore we designed the EFFIcient MOnitoring of
DIabetes (EFFIMODI) study, aiming to make primary
diabetes care as efficient as possible for patients and
health care providers. We hypothesise that six-monthly
monitoring of well-controlled patients with type 2 diabe-
tes in primary care results in equivalent cardiometabolic
control as the currently recommended three-monthly
monitoring, with less costs.
Methods and design
Study design
The study has been designed as a randomised controlled
patient-preference equivalence trial. In practice this
design means that participants are asked if they prefer
three-monthly (usual care) or six-monthly diabetes moni-
toring. If they do not have a preference, they are ran-
domised to a three-monthly or six-monthly monitoring
group. This will result into four study groups (see Figure
1).
We chose to conduct a patient-preference trial because
of two reasons [7]. First, it gives us the possibility to com-
pare the relationship between patients' preference for a
frequency of diabetes control and the study outcomes.
Second, more people will participate in the study, as peo-
ple can choose not to be randomised; they can be
included in the so-called 'observational' study arm of
their choice. Doing so, we will have information about
people who are not randomised and this will help in gen-
eralising the results. In conducting a patient-preference
trial we will avoid selection and probably also drop-out
after randomisation.
We chose to conduct an equivalence trial, because we
want to assess whether six-monthly monitoring results in
equal cardiometabolic control compared to the current
frequency of control [8]. Since we expect that six-
monthly monitoring will not give better cardiometabolic
control than three-monthly monitoring, we did not
choose a non-inferiority trial. The intervention period
will last one and a half year, so patients will be seen either
seven or four times during the intervention period.
The Medical Research Ethics Committee of the Univer-
sity Medical Center Utrecht has approved the study pro-
tocol (Protocol number: 08-453).
Study population
Patients are eligible for the study if they are between 40
and 80 years old, diagnosed with type 2 diabetes for more
than a year, treated by their general practitioner, not on
insulin treatment and overall well-controlled, defined as
having HbA1c ≤7.5% and systolic blood pressure ≤145
mmHg and total cholesterol ≤5.2 mmol/l. These HbA1c,
systolic blood pressure and total cholesterol values are a
little higher than the Dutch target values (HbA1c ≤7.0%,
systolic blood pressure ≤140 mmHg and total cholesterol
Figure 1 Participant flowchart. The participant flowchart with the 
expected number of patients, based on a small survey.
Patients who are eligible 
for the study 
(n = 3000) 
Patients agree to 
participate 
(n = 1800) 
Patients with a  
preference 
(n = 900) 
Patients without a 
preference 
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Three-monthly monitoring
(n = 450) 
Six-monthly monitoring 
(n = 450) 
Patients not interested in 
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(n = 1200) 
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ues to create a larger target population to be randomised.
According to the stricter target values only 18.9% of all
type 2 diabetes patients fulfilled these values [9]. Because
of the minimal difference with the target values, we
assume that 20% of the type 2 diabetes patients will fulfil
the inclusion criteria.
Recruitment of practices and patients
We will approach the boards of several health care groups
to recruit general practitioners. These health care groups
have a central database in which all type 2 diabetes
patients are recorded. In this database all determinants
that are needed for the selection of study patients are
included (see study population for the inclusion crite-
ria). The health care groups will ask all their affiliated
general practitioners to participate in the study. If a gen-
eral practitioner wants to participate he will obtain the
selection of patients, according to the inclusion criteria,
from the health care group. The general practitioner
sends an information letter as well as an informed con-
sent form to the selected patients.
Patients who want to participate have to fill in the
informed consent form. The participants are asked
whether they strongly prefer three-monthly (current
care) or six-monthly diabetes control or whether they
have no preference. Patients with a preference will enter
the 'observational arm'. If participants do not have a
strong preference for the frequency of care, they will be
randomised.
Randomisation and blinding
Participants without a preference for either three-
monthly or six-monthly monitoring are randomised into
one of the two randomised study arms in a 1:1 ratio: a
control group that will receive current care, comprising
diabetes control once per three months, and an interven-
tion group that will receive diabetes control once per six
months. In both randomised groups the extensive annual
check-up will be done by the general practitioner. The
treatment targets, therapeutic algorithms and life style
advices will remain unchanged and do not differ between
the intervention and control groups.
Randomisation is generated at the patient level by a
computerised random-number generator at the Julius
Center. Participants are randomised before baseline data
are collected. Since this is a pragmatic trial, it is not nec-
essary to blind participants and general practitioners for
the treatment allocation. However, the laboratory techni-
cians who measure HbA1c and cholesterol are not aware
of study participation of the patients.
Outcomes
The primary outcome measure is the percentage of peo-
ple that remains under good cardiometabolic control,
defined as having HbA1c ≤7.5% and systolic blood pres-
sure ≤145 mmHg and total cholesterol ≤5.2 mmol/l. Sec-
ondary outcome measures are HbA1c, blood pressure,
cholesterol, Body Mass Index, fasting blood glucose,
smoking behaviour, physical activity, loss of work due to
illness, health status, diabetes-specific distress, satisfac-
tion with treatment and adherence to medications. These
outcomes are collected either from the medical records
or from a patient questionnaire.
Medical records
Biomarkers (HbA1c, cholesterol, fasting blood glucose)
and anthropometric variables (blood pressure, Body
Mass Index) will be collected from the general practitio-
ners' computerised information system. Information on
the most recently measurements of the biomarkers and
anthropometric variables before the study, medical his-
tory, medication use before the study and all measure-
ments performed during the first EFFIMODI visit will be
collected just after the start of the study. All measure-
ments during the follow-up period will be collected after
the end of the follow-up period. The same applies to the
number of diabetes and non-diabetes related visits to the
general practitioner and (differences in) medication use
during the study.
Questionnaires
The participants will be asked to complete an extensive
questionnaire before (t = 0) and after (t = 18 months) the
intervention period. This questionnaire comprises gen-
eral background information on age, gender, ethnicity,
education, smoking, physical activity, occupation and loss
of work due to illness, health status, diabetes-specific dis-
tress and satisfaction with diabetes treatment.
Current smoking is measured as the number of ciga-
rettes per day or the number of cigars per week. Smoking
in the past is measured the same way. Also the number of
pack years is recorded. Physical activity is measured with
the Short Questionnaire to Assess Health-enhancing
physical activity (SQUASH) [10]. The SQUASH is a reli-
able and valid questionnaire to measure the level of phys-
ical activity in an adult population. The questionnaire
was designed to give an indication of the habitual activity
level. Information on light (range: 2-4 Metabolic Equiva-
lent of Task (MET)), moderate (range: 4-6.5 MET) and
vigorous (>6.5 MET) intensity physical activities will be
obtained. Physical activity will be expressed in minutes
per week and in a total activity score. The total activity
score will be calculated by multiplying the minutes per
week by the actual MET score of the specific activity
(MET/min/week).
Occupation and loss of work due to illness are mea-
sured with the Short Form Health and Labour Question-
naire (SF-HLQ) [11]. The SF-HLQ consists of three parts:
absenteeism from paid work, production losses without
absenteeism from paid work and hindrance in the perfor-
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questionnaire will be used to calculate costs of productiv-
ity losses, should incremental cost-effectiveness be mer-
ited at closure of the trial (see economic evaluation).
Two questionnaires are used to measure health status:
Short-Form 36 (SF-36) [12] and EQ-5D [13]. The SF-36
generates a profile of scores on eight dimensions of
health. These dimensions are: (1) physical functioning;
(2) limitations due to physical difficulties (physical role
functioning); (3) bodily pain; (4) social functioning; (5)
mental health; (6) limitations due to emotional difficulties
(emotional role functioning); (7) vitality; and (8) general
health perception. For all eight dimensions an average
score for all items in the scale is calculated, with a range
from 0 (least favourable health state) to 100 (most favour-
able health state). Two summary scales for mental and
physical functioning can be calculated as well. The SF-36
is validated in the Dutch population [14].
The EQ-5D is a generic questionnaire, consisting of a
Visual Analogue Scale (EQ-5D VAS) and a classification
system (EQ-5D Profile) [13]. The EQ-5D Profile covers
five domains of health (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression), each with three
levels of functioning: level 1, no problems; level 2, some
problems; level 3, severe problems. The EQ-5D VAS is a
graded, vertical line, anchored at 0 (worst imaginable
health state) and 100 (best imaginable health state). The
patient is asked to mark a point on the EQ-5D VAS that
best reflects his/her actual health state.
To measure diabetes-specific distress, the Problem
Areas In Diabetes (PAID) questionnaire is used [15]. This
is a widely recognised measure of diabetes distress,
assessing the general emotional burden of diabetes and
distress related to treatment, food choices and social sup-
port. The 20 items are scored on a 5-point scale yielding a
sum score (0-80), with higher scores representing higher
distress. The Dutch PAID scale has good convergent and
discriminate validity and high internal consistency [16].
To measure satisfaction with diabetes treatment, the
Diabetes Treatment Satisfaction Questionnaire (DTSQ)
is used [17]. The DTSQ measures satisfaction with treat-
ment regimen (six items), perceived frequency of hyperg-
lycaemia (one item) and perceived frequency of
hypoglycaemia (one item) over the past few weeks. The
treatment satisfaction score can range from 0 (very dis-
satisfied) to 36 (very satisfied).
Economic evaluation
To be able to calculate direct health care costs, data on
health care use are needed. Data concerning consulta-
tions beyond the planned monitoring consultations,
medication use and referral rates to other health care
professionals will be collected from the general practitio-
ners' computerised Information System. Should this trial
provide evidence that three-monthly monitoring results
in better outcomes than six-monthly monitoring, an
incremental cost-effectiveness analysis becomes war-
ranted, that quantifies the additional cost related to the
additional health effects. For such an economic evalua-
tion we will use data on health care use as recorded in the
information system of the general practitioners, and data
recorded with the SF-HLQ and the EQ5D (see above).
The EQ5D is of special importance, as utilities, and con-
sequently, quality adjusted life years (QALYs) can be elic-
ited using this generic questionnaire.
Sample size calculation
The sample size is calculated on the assumption of equiv-
alence of cardiometabolic control. Therefore, we used the
formula from Jones et al. [8]: n = (2p(100-p)*(Z(1-α)+Z(1-
β))2)/δ2, where p is the overall percentage of successes to
be expected if the treatments are equivalent, δ indicates
the range of equivalence for the difference in percentage
success rates, α is the probability of type I error and β the
probability of type II error.
We assume equivalence if the two-sided 95% confi-
dence interval (α = 0.05; Z(1-α) = 1.96) for the difference in
cardiometabolic control between the two intervention
groups is completely in the range from -5 to 5% (δ = 5).
With a supposed overall percentage of success of 95% and
a power of 90% (β = 0.1; Z(1-β) = 1.28), we need a sample
size of 399 people per randomised group. Based on a
small survey that was performed by the Julius Center, we
assume that ~50% of the people have no preference and
thus will be randomised. About the other half of the peo-
ple is assumed to have a strong preference for the fre-
quency of monitoring. Therefore, we need to include
1596 patients: 798 in the randomised arms and 798 in the
observational arms.
As said earlier in the study population section, we
assume that 20% of the type 2 diabetes patients will fulfil
the inclusion criteria. With an average of 80 type 2 diabe-
tes patients per practice, we expect that sixteen patients
in each general practice will meet the eligibility criteria.
Taking into account a response rate of 60%, ten patients
in each practice will be willing to participate in the study:
five in the observational arm and five in the randomised
arm, so at least 160 general practitioners will have to be
recruited. As people may drop out during the study, we
will recruit 1800 patients allowing an 11% drop-out;
therefore we need 180 general practitioners. Figure 1
shows the participant flowchart with the expected num-
bers.
Analysis
We will use repeated measures analysis for all recorded
measurements of HbA1c, blood pressure, cholesterol and
fasting blood glucose to optimally use all available data.
Data from the questionnaires at the start and at the end of
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Data will be analysed according to intention-to-treat. For
handling missing data we will use multiple imputation
[18]. After the intervention, the randomised three-
monthly and six-monthly monitoring groups are com-
pared on equivalence of cardiometabolic control.
Since this trial is a patient preference trial, we will also
compare the three-monthly preference group with the
three-monthly randomised group. Depending on the
number of patients opting for the six-monthly controls,
we will compare this group with the six-monthly ran-
domised group. In these analyses, we will examine deter-
minants of preference, and we will determine risk profiles
of patients. This will facilitate the applicability of the
results and we can demonstrate if people who are more
motivated will have better cardiometabolic control. Fig-
ure 2 provides an overview of all comparisons that will be
made between the groups.
Economic evaluation
Should this study demonstrate equivalent outcomes with
different frequencies of diabetes monitoring, the evident
cost-reduction of less control visits merit the conclusion
that six-monthly monitoring is the approach of first
choice and a cost-minimisation analysis will be done.
This is likely to provide sufficient evidence to change the
frequency of monitoring in well-controlled type 2 diabe-
tes patients in general practice.
However, should the three-monthly follow-up scheme
result in a better cardiometabolic control, a cost-effec-
tiveness analysis will be performed. If better outcomes
can be realised with a higher control frequency at an
associated higher cost to society, or vice versa, (some-
what) worse patient outcomes at a lower cost, the balance
between costs and outcomes is of interest. Differences in
the number of QALYs between groups during the study
period will be assessed. The difference in treatment effect
will be calculated as follows: for each group the difference
between baseline and final measurements in percentage
of patients with good cardiometabolic control will be
determined. The absolute difference between measure-
ments pre- and post-intervention will be taken as the
intervention effect. Accordingly, differences in QALYs
between groups will be calculated. The 'incremental cost-
effectiveness ratio' (ICER) will be expressed as cost differ-
ences between groups divided by differences in treatment
effects between groups. Confidence intervals will be
determined using bootstrapping [19]. A 'cost-effective-
ness acceptability curve' (CEAC) will also be drawn using
the bootstrap sample. Cost-utility estimates will be
derived accordingly, using QALY differences between
groups as outcome measure.
Discussion
If the results of this study will show that equivalent cardi-
ometabolic control is achieved following six-monthly dia-
betes control in a sub-sample of generally well-controlled
people with type 2 diabetes in general practice as com-
pared to the usual three-monthly diabetes control, their
diabetes control frequency can be reduced. This will
reduce the use of medical services and direct health care
costs, alleviate the burden of a substantial part of the peo-
ple with type 2 diabetes and relieve the workload of dia-
betes nurses. If three-monthly monitoring turns out to
result in a better regulation of diabetes, a cost-effective-
ness analysis is necessary to estimate whether the higher
costs of three-monthly follow-up balance the better
patient outcomes.
The results of this study will provide valuable informa-
tion for health care professionals and policy makers on
cost-effectiveness of diabetes monitoring. In the case of
proven cost-effectiveness, we will recommend imple-
menting a lower control frequency for well-controlled
type 2 diabetes patients.
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